GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Price-to-Owner-Earnings

HLS Therapeutics (HLS Therapeutics) Price-to-Owner-Earnings : (As of Apr. 30, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-30), HLS Therapeutics's share price is $3.56. HLS Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for HLS Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of HLS Therapeutics was 897.65. The lowest was 1.13. And the median was 3.04.


HLTRF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.39
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-30), HLS Therapeutics's share price is $3.56. HLS Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.85. Therefore, HLS Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-30), HLS Therapeutics's share price is $3.56. HLS Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.65. Therefore, HLS Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 13 years, HLS Therapeutics's highest PE Ratio without NRI was 13.52. The lowest was 0.00. And the median was 4.75.


HLS Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for HLS Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Price-to-Owner-Earnings Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 135.57 - - - -

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HLS Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Price-to-Owner-Earnings falls into.



HLS Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

HLS Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.56/-0.31
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (OTCPK:HLTRF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


HLS Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013